726185-68-8

Basic information

• Product Name: 2-PIPERAZIN-1-YL-THIAZOLE-5-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 2-PIPERAZIN-1-YL-THIAZOLE-5-CARBOXYLIC ACID METHYL ESTER;5-Thiazolecarboxylic acid, 2-(1-piperazinyl)-, methyl ester;Methyl 2-(piperazin-1-yl)thiazole-5-carboxylate
• CAS NO: 726185-68-8
• Molecular Formula: C₉H₁₃N₃O₂S
• Molecular Weight: 227.28
• Product Categories: pharmacetical
• Mol File: 726185-68-8.mol

Chemical Properties

• Boiling Point: 366.9°C at 760 mmHg
• Flash Point: 175.7°C
• Appearance: /
• Density: 1.274g/cm³
• Vapor Pressure: 1.42E-05mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-PIPERAZIN-1-YL-THIAZOLE-5-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERAZIN-1-YL-THIAZOLE-5-CARBOXYLIC ACID METHYL ESTER(726185-68-8)
• EPA Substance Registry System: 2-PIPERAZIN-1-YL-THIAZOLE-5-CARBOXYLIC ACID METHYL ESTER(726185-68-8)

Safety Data

• Hazardous Substances Data: 726185-68-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-Piperazin-1-yl-thiazole-5-carboxylic acid methyl ester is used as a building block for the synthesis of new drug candidates due to its potential biological activity and versatile chemical structure.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-Piperazin-1-yl-thiazole-5-carboxylic acid methyl ester is utilized as a drug lead to explore its potential for the treatment of various diseases and conditions, leveraging its prospective therapeutic properties.
Used in the Development of Antibacterial Agents:
2-PIPERAZIN-1-YL-THIAZOLE-5-CARBOXYLIC ACID METHYL ESTER is employed as a key component in the development of novel antibacterial drugs, capitalizing on its ability to target and combat bacterial infections effectively.
Used in the Development of Antifungal Agents:
2-Piperazin-1-yl-thiazole-5-carboxylic acid methyl ester is also used in the creation of new antifungal medications, highlighting its potential to address fungal infections and related health issues.

InChI:InChI=1/C9H13N3O2S/c1-14-8(13)7-6-11-9(15-7)12-4-2-10-3-5-12/h6,10H,2-5H2,1H3

Upstream product

• 864276-97-1 tert-butyl 4-[5-(methoxycarbonyl)-1,3-thiazol-2-yl]piperazine-1-carboxylate 
• 110-85-0 piperazine 
• 72605-86-8 2-chlorothiazole-5-carboxylic acid methyl ester 
• 54045-74-8 methyl 2-bromo-1,3-thiazole-5-carboxylate 
• 464192-28-7 2-bromo-1,3-thiazole-5-carbaldehyde 

Downstream Products

• 864277-00-9 C₁₅H₁₇N₃O₄S₂ 
• 867066-13-5 2-(4-phenylacetyl-piperazin-1-yl)-thiazole-5-carboxylic acid methyl ester 

Relevant articles and documents

Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors

We have designed and synthesized a series of structurally novel hydroxamic acid-based histone deacetylase (HDAC) inhibitors characterized by a zinc chelating head group attached directly to a thiazole ring. The thiazole ring connects to a piperazine spacer, which is capped with a sulfonamide group. These novel molecules potently inhibit an HDAC enzyme mixture derived from HeLa cervical carcinoma cells and show potent antiproliferative activity against the breast cancer cell line MCF7.

AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacyclohexane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

Inhibitors of histone deacetylase

Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least

Inhibitors of histone deacetylase

Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least

Inhibitors of histone deacetylase

Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC.

Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof

The present invention relates to carboxylic acids and esters of general formula wherein Ar, R, R1, X1, X3, X4, Y and Y1 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof, as well as the use thereof for the production and purification of antibodies and as labelled compounds in RIA and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.